NCT05929716

An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: M.D. Anderson Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy of the combination of magrolimab, rituximab, and radiation as bridging therapy in patients with relapsed or refractory LBCL who receive CAR T-Cell Therapy (CART).

Detailed description

Primary Objectives: To evaluate the efficacy of the combination of magrolimab, rituximab and radiation as bridging therapy in patients with relapsed or refractory LBCL who receive CART. Secondary Objectives: To evaluate safety and tolerability of magrolimab, rituximab and radiation as bridging therapy in patients with relapsed or refractory LBCL who receive CART. Exploratory Objective: To determine the pharmacodynamic effects and investigate biomarkers of response and resistance to this bridging therapy.

Conditions

• Large B-cell Lymphoma
• B-cell Lymphoma

Interventions

Type	Name	Description
DRUG	Magrolimab	Given by IV (vein)
DRUG	Rituximab	Given by IV (vein)
DRUG	CAR T leukapheresis	Given by IV (vein)
DRUG	Radiation	Given by IV (vein)

Timeline

• Start date: 2023-09-30
• Primary completion: 2026-03-01
• Completion: 2028-03-01
• First posted: 2023-07-03
• Last updated: 2023-11-13

Regulatory

• FDA-regulated drug study